Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.53 |
| ▸ | DDB1 | Q16531 | 14/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25198443 | 1.00 | CRBN (0.53) | CRBNDDB1POLBGPR119 | |
| SCHEMBL31382214 | 1.00 | CRBN (0.53) | CRBNDDB1POLBGPR119 | |
| SCHEMBL31382681 | 1.00 | CRBN (0.53) | CRBNDDB1POLBGPR119 | |
| SCHEMBL25205685 | 0.94 | CRBN (0.51) | CRBNDDB1POLBGPR119 | |
| SCHEMBL30981254 | 0.91 | CRBN (0.49) | CRBNDDB1POLB | |
| SCHEMBL27023030 | 0.90 | CRBN (0.49) | CRBNDDB1POLBGPR119 | |
| SCHEMBL23301226 | 0.85 | DDB1 (0.67) | CRBNDDB1GPR119 | |
| SCHEMBL21876964 | 0.85 | DDB1 (0.67) | CRBNDDB1GPR119 | |
| SCHEMBL25143422 | 0.85 | CRBN (0.53) | CRBNDDB1POLBGPR119 | |
| SCHEMBL25184923 | 0.85 | CRBN (0.54) | CRBNDDB1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724435-A1 | BIFUNCTIONAL AZINES CONJOGATES AS SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| WO-2024254532-A1 | BIFUNCTIONAL AZINES CONJOGATES AS SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |